Physician profile
David Wallington
NPI 1598384380
$848.55
in general payments reported to CMS, 2019-2025
17 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $213 · 2024: $267 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $369.00 | 2023-2024 | Reflexion Medical Radiotherapy System |
| Boston Scientific Corporation | $123.98 | 2024-2025 | Spaceoar Vue System - 10ml |
| Merck Sharp & Dohme LLC | $60.59 | 2025 | Keytruda, Lynparza |
| Beone Medicines USA, INC. | $25.46 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $25.31 | 2025 | Datroway |
| Sumitomo Pharma America, INC. | $24.20 | 2025 | Orgovyx |
| Abbvie INC. | $23.58 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.12 | 2025 | |
| Genentech USA, INC. | $23.00 | 2025 | Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $20.05 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.44 | 2025 | |
| Geron Corporation | $19.28 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $19.09 | 2025 | Monoferric |
| Blue Earth Diagnostics | $18.67 | 2025 | Posluma |
| Genzyme Corporation | $18.31 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18.23 | 2025 | Imfinzi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.24 | 2025 | Vpriv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wallington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.